BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12820332)

  • 61. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
    Sandhu SS; Symes A; A'Hern R; Sohaib SA; Eisen T; Gore M; Christmas TJ
    BJU Int; 2005 Mar; 95(4):522-5. PubMed ID: 15705072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Influence of tumour-associated symptoms on the prognosis of patients with renal cell carcinoma.
    Kawaciuk I; Hyrsl L; Dusek P; Jarolim L; Schmidt M; Kaliska V; Chocholaty M; Vesely S
    Scand J Urol Nephrol; 2008; 42(5):406-11. PubMed ID: 18932106
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
    Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
    Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
    Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
    Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.
    Jocham D; Richter A; Hoffmann L; Iwig K; Fahlenkamp D; Zakrzewski G; Schmitt E; Dannenberg T; Lehmacher W; von Wietersheim J; Doehn C
    Lancet; 2004 Feb; 363(9409):594-9. PubMed ID: 14987883
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
    Patil S; Ishill N; Deluca J; Motzer RJ
    Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients.
    Amano H; Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Shimada K; Nakazawa H; Ito F; Tanabe K
    Int J Urol; 2010 Jul; 17(7):615-22. PubMed ID: 20482658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma.
    Takaki H; Soga N; Kanda H; Nakatsuka A; Uraki J; Fujimori M; Yamanaka T; Hasegawa T; Arima K; Sugimura Y; Sakuma H; Yamakado K
    Radiology; 2014 Jan; 270(1):292-9. PubMed ID: 23925272
    [TBL] [Abstract][Full Text] [Related]  

  • 71. US-guided percutaneous microwave ablation versus open radical nephrectomy for small renal cell carcinoma: intermediate-term results.
    Yu J; Liang P; Yu XL; Cheng ZG; Han ZY; Zhang X; Dong J; Mu MJ; Li X; Wang XH
    Radiology; 2014 Mar; 270(3):880-7. PubMed ID: 24475805
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.
    Abdollah F; Suardi N; Capitanio U; Matloob R; Fossati N; Castiglione F; Di Trapani E; Di Trapani D; Russo A; Carenzi C; Montorsi F; Rigatti P; Bertini R
    Urol Oncol; 2014 Jan; 32(1):43.e9-16. PubMed ID: 23911684
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].
    May M; Kendel F; Hoschke B; Gilfrich C; Kiessig S; Pflanz S; Seidel M; Brookman-Amissah S
    Urologe A; 2009 Sep; 48(9):1075-83. PubMed ID: 19562320
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinicopathological study of renal cell carcinoma.
    Nakatani T; Yoshida N; Iwata H; Kuratsukuri K; Uchida J; Kawashima H; Ikemoto S; Sugimura K
    Oncol Rep; 2003; 10(3):679-85. PubMed ID: 12684643
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
    Clark JI; Atkins MB; Urba WJ; Creech S; Figlin RA; Dutcher JP; Flaherty L; Sosman JA; Logan TF; White R; Weiss GR; Redman BG; Tretter CP; McDermott D; Smith JW; Gordon MS; Margolin KA
    J Clin Oncol; 2003 Aug; 21(16):3133-40. PubMed ID: 12810695
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression of plakoglobin in renal cell carcinoma.
    Buchner A; Oberneder R; Riesenberg R; Keiditsch E; Hofstetter A
    Anticancer Res; 1998; 18(6A):4231-5. PubMed ID: 9891472
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Primary metastasized hypernephroma: therapy and follow-up].
    Hienert VG; Latal D; Kühböck J; Rummelhardt S
    Z Urol Nephrol; 1987 Dec; 80(12):669-74. PubMed ID: 3442132
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Native nephrectomy for renal cell carcinoma in transplant recipients.
    Suson KD; Sausville JE; Sener A; Phelan MW
    Transplantation; 2011 Jun; 91(12):1376-9. PubMed ID: 21512434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.